About Nucleus Genomics
Nucleus Genomics is a Healthcare company based in Manhattan (United States) founded in 2021 by Kian Sadeghi. Provider of genetic testing kits for rare variant analysis. Nucleus Genomics has raised $31.5 million across 3 funding rounds from investors including Neo, Seven Seven Six and Balaji Srinivasan. Nucleus Genomics has completed 2 acquisitions, including Cambrean and Impute.me. Its chief executive, as recorded, is Kian Sadeghi. Its website mynucleus.com draws about 269 thousand monthly visits. Nucleus Genomics offers products and services including DNA Health Test and Whole-Genome Test. Its focus areas include HealthTech, Healthcare Booking Platforms, Diagnostics and Internet First Clinical Labs. Its legal entity is Nucleus Genomics, Inc. Its competitors include ArcherDX, Natera and Variantyx; 3 of its 3 listed competitors have raised funding.
Company details
Nucleus Genomics was established in 2021 in Manhattan, United States, within the genomics sector. A direct-to-consumer platform is operated, where whole-genome sequencing is utilized to deliver genetic risk and disposition score analyses. These services cover an extensive array of diseases and traits, with a focus on rare variant detection through at-home testing kits. Operations are centered on accessible genetic insights for individual users.
- Headquarters Manhattan, United States
- Founders Kian Sadeghi
- SectorsHealthcare
- Website category Health · Mens Health
- Website mynucleus.com
- Social LinkedIn X YouTube
- Legal Name Nucleus Genomics, Inc.
Products & Services of Nucleus Genomics
Nucleus Genomics offers a comprehensive portfolio of products and services, including DNA Health Test and Whole-Genome Test.
Analyzes genetic risks for over 900 health conditions including cancers.
Sequences full genome for insights on diseases and longevity factors.
Apps and channels of Nucleus Genomics
its YouTube channel Nucleus Genomics has 684 subscribers and 18 videos.
Videos from Nucleus Genomics
The most watched videos on Nucleus Genomics's YouTube channel, Nucleus Genomics (684 subscribers). Click a video to play it here.
More on Nucleus Genomics.
Funding Insights of Nucleus Genomics
Nucleus Genomics has successfully raised a total of $31.5M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $14 million completed in January 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $31.5M
- Total Rounds 3
- Last Round Series A — $14M
- First Round $3.5M
(Dec 2021)
- Investors Count 26
All 3 funding rounds of Nucleus Genomics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2025 | $14M | Series A | – | – | |
| Jul 2022 | $14M | Series A | – | – | |
| Dec 2021 | $3.5M | Seed | – | Founders Fund |
26 investors in total: 10 institutional and 16 angel.
Investors in Nucleus Genomics
Nucleus Genomics has secured backing from 26 investors, including venture fund and angel investors. Prominent investors backing the company include Neo, Seven Seven Six and Balaji Srinivasan.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital fund focused on investing in technology startups | sevensevensix.com | Austin, United States | ||
Technology startups are accelerated and incubated sector-agnostically by Neo. | 2017 | neo.com | San Francisco, United States | |
Venture capital investments are made in deep tech innovations. | giantstep.vc | |||
| oneeightcapital.com | ||||
Venture capital investments in technology and defense sectors. | foundersfund.com | |||
Consumer funds are targeted by this venture capital firm. | shrug.vc | San Francisco, United States | ||
Early-stage investments and venture studio services are provided by Pareto Holdings. | pareto20.com | Miami, United States | ||
Investments are managed by Quiet Capital in New York. | quiet.com | New York, United States | ||
| saltfund.tcc.mode | ||||
| bluewatchventures.com |
Investor details for Nucleus Genomics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Nucleus Genomics
7 people are tracked at Nucleus Genomics (4 in leadership, 3 in team).
| Name | Role | Group |
|---|---|---|
Kian Sadeghi | Founder & CEO | Leadership |
Lasse Folkersen | Chief Scientific Officer | Leadership |
Chris F. | Head Of Operations | Leadership |
Savraj Singh | Chief Technology Officer | Leadership |
David S. | Product & Design | Team |
mustafa şener | Computer Programmer | Team |
Ziwen Hou | Software Engineer | Team |
Complete people profiles for Nucleus Genomics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Nucleus Genomics
Nucleus Genomics has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Cambrean and Impute.me.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Digital health analytics for businesses are provided via a platform. | cambrean.com | San Francisco, United States | 2021 | Jan 2025 | •••• | |
Non-profit tools utilizing data services are provided by Impute.me. | impute.me | France | 2015 | Jul 2022 | •••• |
Complete acquisition details for Nucleus Genomics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Nucleus Genomics
5 dated milestones of Nucleus Genomics across 4 years, from founding to its latest funding, stage changes and deals.
Competitors of Nucleus Genomics
Nucleus Genomics has 3 listed competitors in our database, 3 of them funded. They include ArcherDX, Natera and Variantyx.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| archerdx.com | 2013 | Boulder, United States | $152.6M | 429 | Molecular cancer diagnostic products are developed using patented AMP technology. | |
| natera.com | 2004 | Redwood, United States | $152.1M | 3,293 | Developer of cell-free DNA testing for oncology, women’s health, and organ health | |
| variantyx.com | 2014 | Boston, United States | $110.5M | 122 | Genomics data analysis platform for healthcare diagnostics is offered. |
Detailed competitors of Nucleus Genomics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Nucleus Genomics
The website of Nucleus Genomics (mynucleus.com) receives about 269.2K visits a month and ranks #133,887 among all websites worldwide, #4,040 in Mens Health.
- Monthly visits269.2K
▼ 27.3% vs previous month
- Unique visitors178.3K
per month
- Global rank#133,887
among all websites
- Category rank#4,040
Health · Mens Health
- Bounce rate46%
- Pages per visit2.4
- Average visit1 min 40 sec
- DevicesDesktop 25% · Mobile 75%
Websites whose visitors overlap most with Nucleus Genomics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
sleephealthsolutionsohio.com | sleephealthsolutionsohio.com | 100% | #583,693 | – | |
fastlifehacks.com | fastlifehacks.com | 93% | #449,629 | – | |
| mitohealth.com | 91% | 185.5K | #283,180 | View details | |
peterattiamd.com | peterattiamd.com | 87% | #80,123 | – | |
| sleep.me | 85% | 211.7K | #213,928 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 34 similar websites and full traffic analytics for Nucleus Genomics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 34 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Nucleus Genomics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Nucleus Genomics
Complete news archive for Nucleus Genomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nucleus Genomics
Nucleus Genomics was founded in 2021.
Nucleus Genomics is headquartered in Manhattan, United States. It is registered at Manhattan, New York, United States.
Kian Sadeghi is the CEO of Nucleus Genomics, as recorded in our data. They have also founded this company.
Nucleus Genomics is a funded company, having raised a total of $31.5M across 3 funding rounds to date. The company's 1st funding round was a Seed of $3.5M, raised on Dec 2021.
Nucleus Genomics was established in 2021 in Manhattan, United States, within the genomics sector. A direct-to-consumer platform is operated, where whole-genome sequencing is utilized to deliver genetic risk and disposition score analyses. These services cover an extensive array of diseases and traits, with a focus on rare variant detection through at-home testing kits. Operations are centered on accessible genetic insights for individual users.
Nucleus Genomics offers DNA Health Test and Whole-Genome Test.
Nucleus Genomics has 26 investors. Key investors include Neo, Seven Seven Six, Balaji Srinivasan, Achal Upadhyaya, and Giant Step Capital.
Nucleus Genomics operates through Nucleus Genomics, Inc..
The website of Nucleus Genomics receives about 269 thousand visits a month and ranks #133,887 among all websites worldwide.